Cargando…

Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study

Guselkumab is an IL‐23 inhibitor that has been demonstrated to be effective and safe for the treatment of moderate‐to‐severe plaque psoriasis in clinical trials. The data pool relating to the use of guselkumab in a real‐life setting is still lacking. To evaluate the efficacy and safety of guselkumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Zenone, Mattia, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786539/ https://www.ncbi.nlm.nih.gov/pubmed/35762118 http://dx.doi.org/10.1111/dth.15670

Ejemplares similares

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
por: Mastorino, Luca, et al.
Publicado: (2022)

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022)

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
por: MASTORINO, Luca, et al.
Publicado: (2022)

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study
por: Mastorino, Luca, et al.
Publicado: (2021)

Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
por: Mastorino, Luca, et al.
Publicado: (2022)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs
por: Burzi, Lorenza, et al.
Publicado: (2022)

Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
por: Miniotti, Marco, et al.
Publicado: (2022)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023)

The Skin Microbiome and Its Role in Psoriasis: A Review
por: Celoria, Valentina, et al.
Publicado: (2023)

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
por: Avallone, Gianluca, et al.
Publicado: (2023)

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient
por: Quaglino, Pietro, et al.
Publicado: (2021)

Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center
por: Roccuzzo, Gabriele, et al.
Publicado: (2023)

Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report
por: Gelato, Federica, et al.
Publicado: (2022)

Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies
por: Ricci, Alessia Andrea, et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Alopecia areata after COVID-19 vaccination
por: Gallo, Giuseppe, et al.
Publicado: (2022)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

Immunotherapy in transplanted patients: A special population that can no longer be ignored
por: Rubatto, Marco, et al.
Publicado: (2021)

Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report
por: AGOSTINI, Andrea, et al.
Publicado: (2021)

Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single‐centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course
por: Macagno, N., et al.
Publicado: (2022)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Association between Primary Cutaneous B-cell Lymphomas and Other Skin Cancers: A Multicentre Cohort Study
por: AVALLONE, Gianluca, et al.
Publicado: (2022)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Time to next treatment and safety assessment in cutaneous‐T‐cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
por: Rubatto, Marco, et al.
Publicado: (2023)

Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic
por: Maronese, Carlo Alberto, et al.
Publicado: (2022)

SPECT/CT-Guided Surgical Removal of a Positive External Iliac Sentinel Node in Primary Umbilical Melanoma: Report of a Case, and Up-to-Date Review of the Literature
por: Picciotto, Franco, et al.
Publicado: (2022)

Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications
por: Tonella, Luca, et al.
Publicado: (2021)

Guselkumab for plaque psoriasis
Publicado: (2019)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Non-Sentinel Lymph Node Detection during Sentinel Lymph Node Biopsy in Not-Complete-Lymph-Node-Dissection Era: A New Technique for Better Staging and Treating Melanoma Patients
por: Picciotto, Franco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q2qep91sub1n6jdds5qj3ic168